Cunningham G, Hughes J, Borner B, et al. - A randomized control trial was designed to evaluate whether a single dose of tranexamic acid reduces blood loss after reverse and anatomic shoulder arthroplasty. Researchers performed a double-blinded randomized controlled trial to compare intravenous tranexamic acid (TXA) with placebo in 60 patients undergoing primary anatomic and reverse shoulder arthroplasty. They administered placebo to 29 patients whilst 31 received a single dose of 2g of intravenous TXA. They recorded patient demographics as well as drain tube output, blood loss, hematoma formation, transfusion requirement, length of hospital stay, and pain scores. The results of this study exhibited that a single dose of 2g intravenous Tranexamic Acid decreases blood loss and drain tube output in primary anatomic and reverse arthroplasty of the shoulder. No differences were observed in the occurrence of complications, need for transfusion, pain scores, or length of hospital stay. The outcomes revealed that individuals undergoing an elective primary shoulder arthroplasty should be given intravenous TXA to reduce peri-operative blood loss.